CM338
Phase 2Small molecule
CM338 is one of 29 small molecule programs targeting Nephropathy. It is currently in Phase 2.
1
Indications
3
Total Trials
1
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
35 competitors in Nephropathy
#DrugCompanyPhaseTrials
1Alka-Seltzer
AAbbott
Approved
Rocaltrol
Jazz PharmaceuticalsApproved
Theo-Dur
PfizerApproved
Rituxan
RocheApproved
Crestor
AstraZenecaApproved
Micardis
Boehringer IngelheimApproved
Zocor
OOrganon and Co
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Nitrostat
VViatris Specialty LLC
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CM338. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- KKeymed Biosciences Co.Ltd